The remarkable clinical activity of PD-1 inhibitors in HL is driven by the genetic reprogramming of HRS cells to evade immune surveillance through the PD-1/PD-L1 axis, with amplification of 9p24.1 and the presence of MCH class II being the most predictive positive biomarkers of response. The gene discussed is CD274; the disease is Hodgkins lymphoma.